Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Emma F Barry is active.

Publication


Featured researches published by Emma F Barry.


Cell Stem Cell | 2009

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

Liqing Jin; Erwin M. Lee; Hayley S. Ramshaw; Samantha J. Busfield; Armando G. Peoppl; Lucy Wilkinson; Mark A. Guthridge; Daniel Thomas; Emma F Barry; Andrew W. Boyd; David P. Gearing; Gino Vairo; Angel F. Lopez; John E. Dick; Richard B. Lock

Leukemia stem cells (LSCs) initiate and sustain the acute myeloid leukemia (AML) clonal hierarchy and possess biological properties rendering them resistant to conventional chemotherapy. The poor survival of AML patients raises expectations that LSC-targeted therapies might achieve durable remissions. We report that an anti-interleukin-3 (IL-3) receptor alpha chain (CD123)-neutralizing antibody (7G3) targeted AML-LSCs, impairing homing to bone marrow (BM) and activating innate immunity of nonobese diabetic/severe-combined immunodeficient (NOD/SCID) mice. 7G3 treatment profoundly reduced AML-LSC engraftment and improved mouse survival. Mice with pre-established disease showed reduced AML burden in the BM and periphery and impaired secondary transplantation upon treatment, establishing that AML-LSCs were directly targeted. 7G3 inhibited IL-3-mediated intracellular signaling of isolated AML CD34(+)CD38(-) cells in vitro and reduced their survival. These results provide clear validation for therapeutic monoclonal antibody (mAb) targeting of AML-LSCs and for translation of in vivo preclinical research findings toward a clinical application.


Molecular Cell | 2000

Site-Specific Serine Phosphorylation of the IL-3 Receptor Is Required for Hemopoietic Cell Survival

Mark A. Guthridge; Frank C. Stomski; Emma F Barry; Wendy Winnall; Joanna M. Woodcock; Barbara J. McClure; Mara Dottore; Michael C. Berndt; Angel F. Lopez

In the hemopoietic compartment, IL-3, GM-CSF, and IL-5 receptors are major transducers of survival signals; however, the receptor-proximal events that determine this vital function have not been defined. We have found that IL-3 stimulation induces phosphorylation of Ser-585 of beta(c). This promotes the association of phospho-Ser-585 of beta(c) with 14-3-3 and the p85 subunit of PI 3-K. Mutation of Ser-585 specifically impairs the PI 3-K signaling pathway and reduces cell survival in response to IL-3. These results define a distinct IL-3 receptor-mediated survival pathway regulated by site-specific receptor serine phosphorylation and 14-3-3 binding and suggest that this novel mode of signaling may be utilized by disparate transmembrane receptors that have as a common theme the transduction of survival signals.


The EMBO Journal | 2006

Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch.

Mark A. Guthridge; Jason A. Powell; Emma F Barry; Frank C. Stomski; Barbara J. McClure; Hayley S. Ramshaw; Fernando A Felquer; Mara Dottore; Daniel Thomas; Bik To; C. Glenn Begley; Angel F. Lopez

Pleiotropism is a hallmark of cytokines and growth factors; yet, the underlying mechanisms are not clearly understood. We have identified a motif in the granulocyte macrophage‐colony‐stimulating factor receptor composed of a tyrosine and a serine residue that functions as a binary switch for the independent regulation of multiple biological activities. Signalling occurs either through Ser585 at lower cytokine concentrations, leading to cell survival only, or through Tyr577 at higher cytokine concentrations, leading to cell survival as well as proliferation, differentiation or functional activation. The phosphorylation of Ser585 and Tyr577 is mutually exclusive and occurs via a unidirectional mechanism that involves protein kinase A and tyrosine kinases, respectively, and is deregulated in at least some leukemias. We have identified similar Tyr/Ser motifs in other cell surface receptors, suggesting that such signalling switches may play important roles in generating specificity and pleiotropy in other biological systems.


Blood | 2013

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription

Daniel Thomas; Jason A. Powell; François Vergez; David Segal; Nhu-Y Nguyen; Adele Baker; Tse-Chieh Teh; Emma F Barry; Jean-Emmanuel Sarry; Erwin M. Lee; Tracy L. Nero; Anissa M. Jabbour; Giovanna Pomilio; Benjamin D Green; Stéphane Manenti; Stefan P. Glaser; Michael W. Parker; Angel F. Lopez; Paul G. Ekert; Richard B. Lock; David C. S. Huang; Susan K. Nilsson; Christian Recher; Andrew Wei; Mark A. Guthridge

Resistance to cell death is a hallmark of cancer and renders transformed cells resistant to multiple apoptotic triggers. The Bcl-2 family member, Mcl-1, is a key driver of cell survival in diverse cancers, including acute myeloid leukemia (AML). A screen for compounds that downregulate Mcl-1 identified the kinase inhibitor, PIK-75, which demonstrates marked proapoptotic activity against a panel of cytogenetically diverse primary human AML patient samples. We show that PIK-75 transiently blocks Cdk7/9, leading to transcriptional suppression of MCL-1, rapid loss of Mcl-1 protein, and alleviation of its inhibition of proapoptotic Bak. PIK-75 also targets the p110α isoform of PI3K, which leads to a loss of association between Bcl-xL and Bak. The simultaneous loss of Mcl-1 and Bcl-xL association with Bak leads to rapid apoptosis of AML cells. Concordantly, low Bak expression in AML confers resistance to PIK-75-mediated killing. On the other hand, the induction of apoptosis by PIK-75 did not require the expression of the BH3 proteins Bim, Bid, Bad, Noxa, or Puma. PIK-75 significantly reduced leukemia burden and increased the survival of mice engrafted with human AML without inducing overt toxicity. Future efforts to cotarget PI3K and Cdk9 with drugs such as PIK-75 in AML are warranted.


Journal of Biological Chemistry | 2009

14-3-3:Shc Scaffolds Integrate Phosphoserine and Phosphotyrosine Signaling to Regulate Phosphatidylinositol 3-Kinase Activation and Cell Survival

Emma F Barry; Fernando A Felquer; Jason A. Powell; Lisa Biggs; Frank C. Stomski; Andrea Urbani; Hayley S. Ramshaw; Peter Hoffmann; Matthew C. J. Wilce; Michele A. Grimbaldeston; Angel F. Lopez; Mark A. Guthridge

Integrated cascades of protein tyrosine and serine/threonine phosphorylation play essential roles in transducing signals in response to growth factors and cytokines. How adaptor or scaffold proteins assemble signaling complexes through both phosphotyrosine and phosphoserine/threonine residues to regulate specific signaling pathways and biological responses is unclear. We show in multiple cell types that endogenous 14-3-3ζ is phosphorylated on Tyr179 in response to granulocyte macrophage colony-stimulating factor. Importantly, 14-3-3ζ can function as an intermolecular bridge that couples to phosphoserine residues and also directly binds the SH2 domain of Shc via Tyr179. The assembly of these 14-3-3:Shc scaffolds is specifically required for the recruitment of a phosphatidylinositol 3-kinase signaling complex and the regulation of CTL-EN cell survival in response to cytokine. The biological significance of these findings was further demonstrated using primary bone marrow-derived mast cells from 14-3-3ζ-/- mice. We show that cytokine was able to promote Akt phosphorylation and viability of primary mast cells derived from 14-3-3ζ-/- mice when reconstituted with wild type 14-3-3ζ, but the Akt phosphorylation and survival response was reduced in cells reconstituted with the Y179F mutant. Together, these results show that 14-3-3:Shc scaffolds can act as multivalent signaling nodes for the integration of both phosphoserine/threonine and phosphotyrosine pathways to regulate specific cellular responses.


PLOS Biology | 2013

Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival.

Daniel Thomas; Jason A. Powell; Benjamin D Green; Emma F Barry; Yuefang Ma; Joanna M. Woodcock; Stephen Fitter; Andrew C.W. Zannettino; Stuart M. Pitson; Timothy P. Hughes; Angel F. Lopez; Peter R. Shepherd; Andrew Wei; Paul G. Ekert; Mark A. Guthridge

The protein kinase activity of PI3K phosphorylates specific serine residues in growth factor receptors to promote cell survival; these events are constitutively activated in some leukemias.


Molecular and Cellular Biology | 2008

Fibroblast growth factor receptor 2 phosphorylation on Serine 779 couples to 14-3-3 and regulates cell survival and proliferation

Ana Lonic; Emma F Barry; Cindy Quach; Bostjan Kobe; Neil F. W. Saunders; Mark A. Guthridge

ABSTRACT The fibroblast growth factors (FGFs) exert their diverse (or pleiotropic) biological responses through the binding and activation of specific cell surface receptors (FGFRs). While FGFRs are known to initiate intracellular signaling through receptor tyrosine phosphorylation, the precise mechanisms by which the FGFRs regulate pleiotropic biological responses remain unclear. We now identify a new mechanism by which FGFR2 is able to regulate intracellular signaling and cellular responses. We show that FGFR2 is phosphorylated on serine 779 (S779) in response to FGF2. S779, which lies adjacent to the phospholipase Cγ binding site at Y766, provides a docking site for the 14-3-3 phosphoserine-binding proteins and is essential for the full activation of the phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase pathways. Furthermore, S779 signaling is essential for promoting cell survival and proliferation in both Ba/F3 cells and BALB/c 3T3 fibroblasts. This new mode of FGFR2 phosphoserine signaling via the 14-3-3 proteins may provide an increased repertoire of signaling outputs to allow the regulation of pleiotropic biological responses. In this regard, we have identified conserved putative phosphotyrosine/phosphoserine motifs in the cytoplasmic domains of diverse cell surface receptors, suggesting that they may perform important functional roles beyond the FGFRs.


PLOS ONE | 2013

High Yield Production of a Soluble Human Interleukin-3 Variant from E. coli with Wild-Type Bioactivity and Improved Radiolabeling Properties

Timothy R. Hercus; Emma F Barry; Mara Dottore; Barbara J. McClure; Andrew I. Webb; Angela F Lopez; Ian G. Young; James M. Murphy

Human interleukin-3 (hIL-3) is a polypeptide growth factor that regulates the proliferation, differentiation, survival and function of hematopoietic progenitors and many mature blood cell lineages. Although recombinant hIL-3 is a widely used laboratory reagent in hematology, standard methods for its preparation, including those employed by commercial suppliers, remain arduous owing to a reliance on refolding insoluble protein expressed in E. coli. In addition, wild-type hIL-3 is a poor substrate for radio-iodination, which has been a long-standing hindrance to its use in receptor binding assays. To overcome these problems, we developed a method for expression of hIL-3 in E. coli as a soluble protein, with typical yields of >3mg of purified hIL-3 per litre of shaking microbial culture. Additionally, we introduced a non-native tyrosine residue into our hIL-3 analog, which allowed radio-iodination to high specific activities for receptor binding studies whilst not compromising bioactivity. The method presented herein provides a cost-effective and convenient route to milligram quantities of a hIL-3 analog with wild-type bioactivity that, unlike wild-type hIL‑3, can be efficiently radio-iodinated for receptor binding studies.


Blood | 2003

The phosphoserine-585–dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-κB and induction of bcl-2

Mark A. Guthridge; Emma F Barry; Fernando A Felquer; Barbara J. McClure; Frank C. Stomski; Hayley S. Ramshaw; Angel F. Lopez


Cell Reports | 2014

Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody

Sophie E. Broughton; Timothy R. Hercus; Matthew P. Hardy; Barbara J. McClure; Tracy L. Nero; Mara Dottore; Huy Huynh; Hal Braley; Emma F Barry; Winnie L. Kan; Urmi Dhagat; Pierre Scotney; Dallas Hartman; Samantha J. Busfield; Catherine M. Owczarek; Andrew D. Nash; Nicholas J. Wilson; Michael W. Parker; Angel F. Lopez

Collaboration


Dive into the Emma F Barry's collaboration.

Top Co-Authors

Avatar

Angel F. Lopez

University of South Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Barbara J. McClure

University of South Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mara Dottore

University of South Australia

View shared research outputs
Top Co-Authors

Avatar

Jason A. Powell

Institute of Medical and Veterinary Science

View shared research outputs
Top Co-Authors

Avatar

Frank C. Stomski

Walter and Eliza Hall Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Hayley S. Ramshaw

University of South Australia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joanna M. Woodcock

Institute of Medical and Veterinary Science

View shared research outputs
Researchain Logo
Decentralizing Knowledge